Marc Lichtenfeld at The Smart Profits Report says he’s found an “immense” investment opportunity in a small-cap biotech firm.

There are three entry points in biotech stocks. They are: The first stages of research for a new drug; the initial human trial phases; and immediately before the drug is FDA approved. The later the entry point, the safer the investment.

The stock Marc has his eye on is a late-stage company. It is finishing Phase III trials for a unique cancer treatment drug which, if successful, will corner an entire market.

This from Marc:

The easiest and safest time to invest in a small-cap biotech is after the drug receives approval. However, those investors will obviously not have the same return as those who were willing to take on more risk.

For investors who can afford to stick with the drug approval process, the profits can be life-altering when the drug gets approved and eventually goes on to be a big seller.

For example, investors who sunk $10,000 into Celgene (NASDAQ:CELG) ten years ago have over $1.4 million today.

So how do you grab a piece of the pie?

This is one stock that I am extremely excited about.

So much so, in fact, that I just released an in-depth report on it in my small-cap healthcare investing service, Access.

It’s a late-stage company that I believe is poised to be the next Celgene – the stock that turned investors’ $10,000 into over $1.4 million.

The opportunity is immense. The company is just wrapping up Phase III trials for a cancer treatment that currently has no approved drugs to treat it. Needless to say, if this tiny company is successful, it will have the market to itself.

Even The FDA Wants This One On The Market

What I especially like is the rigorous way that the company designed its Phase II trial, where it ran a randomized double-blind placebo controlled trial. This is not something you see too often in oncology.

Not only that, the results showed that the progression free survival (PFS) rate of all patients taking the drug doubled.  A subset of patients saw their PFS rate quadruple.

This increases my confidence that Phase III will confirm the effectiveness of the drug. Even the FDA wants this drug on the market (assuming it’s safe and effective, of course). The agency has fast-tracked it and granted it “orphan drug status.” This means it will speed up the approval process because of the dire need for the drug and the company will get seven extra years of patent protection.

And to top it all off, the market for this drug is three times the size of Celgene’s. So you can see why I’m so excited about this recommendation.

Here’s How To Invest In This Company

Time is of the essence here. This week, the company is kicking off its road show to institutional investors and getting the story out to the masses. This will surely attract interest. Once institutions get on board, the stock is going to move beyond our recommended price.

Additionally, we’re holding an exclusive, private conference call for Access subscribers, featuring the company’s CEO and a cancer expert. It takes place on Wednesday, September 10 at 2:00 p.m. ET. But in order to be eligible to participate in the call, you must be signed up by midnight on September 6.

For information on Access and this incredible opportunity, please click here.

Source: How To Make Money In The Three Stages Of Biotech Investing